Figure S1 from Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
Year: 2023
Type: other
Abstract: Supplemental Figure S1. Kaplan-Meier analysis of the progression free survival (PFS) of patients on each treatment arm stratified by BRCA status showed no significant differences.
Authors: Shivaani Kummar, Amit M. Oza, Gini F. Fleming, Daniel M. Sullivan, David R. Gandara, Michael J. Naughton, Miguel A. Villalona-Calero, Robert J. Morgan, Peter M. Szabo, Ahrim Youn, Alice P. Chen, Jiuping Ji, Deborah E. Allen, Chih-Jian Lih, Michele G. Mehaffey, William D. Walsh, Paul M. McGregor, Seth M. Steinberg, P. Mickey Williams, Robert J. Kinders, Barbara A. Conley, Richard M. Simon, James H. Doroshow
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361818397